124 related articles for article (PubMed ID: 38251444)
21. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study.
Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H
Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914
[TBL] [Abstract][Full Text] [Related]
22. HCV elimination in a Swiss opioid agonist therapy programme - a cohort study.
Bregenzer A; Krismer C; Wendel S; Roser P; Fux CA
Swiss Med Wkly; 2022 Dec; 152():40009. PubMed ID: 36509421
[TBL] [Abstract][Full Text] [Related]
23. Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors.
Bova S; Cameron A; Durand C; Katzianer J; LeGrand M; Boyer L; Glorioso J; Toman LP
Am J Health Syst Pharm; 2022 Jan; 79(3):173-178. PubMed ID: 33987658
[TBL] [Abstract][Full Text] [Related]
24. A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study.
Braun DL; Hampel B; Ledergerber B; Grube C; Nguyen H; Künzler-Heule P; Shah C; Salazar-Vizcaya L; Conen A; Flepp M; Stöckle M; Béguelin C; Schmid P; Rougemont M; Delaloye J; Bernasconi E; Nicca D; Böni J; Rauch A; Kouyos RD; Günthard HF; Fehr JS
Clin Infect Dis; 2021 Oct; 73(7):e2194-e2202. PubMed ID: 32761122
[TBL] [Abstract][Full Text] [Related]
25. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
[TBL] [Abstract][Full Text] [Related]
26. Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study.
Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV
Clin Infect Dis; 2020 Sep; 71(6):1502-1510. PubMed ID: 31585005
[TBL] [Abstract][Full Text] [Related]
27. Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States.
Chen PH; Yenokyan K; Fojo AT; Hutton HE; Lesko CR; McCaul ME; Yang C; Cachay ER; Crane HM; Jacobson JM; Kim HN; Kitahata MM; Mayer KH; Moore RD; Napravnik S; Saag M; Lau B; Chander G
Drug Alcohol Depend; 2022 Dec; 241():109673. PubMed ID: 36332596
[TBL] [Abstract][Full Text] [Related]
28. On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017.
Aas CF; Vold JH; Skurtveit S; Odsbu I; Chalabianloo F; Økland JM; Leiva RAM; Vickerman P; Johansson KA; Fadnes LT
BMJ Open; 2020 Aug; 10(8):e036355. PubMed ID: 32847908
[TBL] [Abstract][Full Text] [Related]
29. Liver Disease Screening and Hepatitis C Virus Elimination in Taiwan Rural Indigenous Townships: Village-By-Village Screening and Linking to Outreach Hepatology Care.
Tien HM; Cheng TC; Lien HC; Yang KF; Shy CG; Chen YL; Hsu NT; Lu SN; Wang JH
Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35328957
[TBL] [Abstract][Full Text] [Related]
30. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
31. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
Doyle JS; Scott N; Sacks-Davis R; Pedrana AE; Thompson AJ; Hellard ME;
Aliment Pharmacol Ther; 2019 May; 49(9):1223-1229. PubMed ID: 30908706
[TBL] [Abstract][Full Text] [Related]
32. Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project.
Ponziani FR; Santopaolo F; Siciliano M; De Belvis AG; Tortora A; Mora V; Fanali C; Morsella A; Balducci F; Vetrugno G; D'Alfonso ME; Cambieri A; Cauda R; Bellantone R; Sanguinetti M; Pompili M; Gasbarrini A
J Viral Hepat; 2021 Apr; 28(4):651-656. PubMed ID: 33421220
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study.
Wu VC; Huang CH; Wang CL; Lin MH; Kuo TY; Chang CH; Wu M; Chen SW; Chang SH; Chu PH; Wu CS; Lin YS
Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):507-514. PubMed ID: 37170917
[TBL] [Abstract][Full Text] [Related]
35. Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project.
Villamil FG; Massenzio NE; Baré PC; Cocco PA; Cairo FM; Picchio GR
Ann Hepatol; 2022 Jan; 27 Suppl 1():100577. PubMed ID: 34740846
[TBL] [Abstract][Full Text] [Related]
36. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
37. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
38. Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort.
Clark PJ; Valery PC; Strasser SI; Weltman M; Thompson AJ; Levy M; Leggett B; Zekry A; Rong J; Angus P; George J; Bollipo S; McGarity B; Sievert W; Macquillan G; Tse E; Nicoll A; Wade A; Chu G; Harding D; Cheng W; Farrell G; Roberts SK
Dig Dis Sci; 2023 Jan; 68(1):291-303. PubMed ID: 35552941
[TBL] [Abstract][Full Text] [Related]
39. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.
Aas CF; Vold JH; Skurtveit S; Odsbu I; Chalabianloo F; Lim AG; Johansson KA; Fadnes LT
Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):44. PubMed ID: 32605625
[TBL] [Abstract][Full Text] [Related]
40. Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study.
Brezzi M; Bertisch B; Roelens M; Moradpour D; Terziroli Beretta-Piccoli B; Semmo N; Müllhaupt B; Semela D; Negro F; Keiser O;
PLoS One; 2019; 14(6):e0218706. PubMed ID: 31233524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
